| Name | Title | Contact Details |
|---|
We Are The Immune System Company™ In 1998, Founders David and Bianca Lisonbee embarked on a journey to bring 4Life Transfer Factor® products to the world. Everything we do at 4Life is guided by our 4 Values: Science, Success, Service, and Satisfaction.
APER Solutions is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InnovAge helps seniors age in their own homes with dignity through the Program of All-inclusive Care for the Elderly (PACE). InnovAge is dedicated to expanding this successful program to serve as many seniors as possible across the country. We hire exceptional people for our programs in California, Colorado, New Mexico, Pennsylvania, and Virginia. Our mission is to sustain and enhance the independence and quality of life for those we serve, on their terms. Our purpose is to help older adults remain mobile, prolong their health, and continue living in their own homes.
A-Dec, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Newberg, OR. To find more information about A-Dec, Inc., please visit www.a-dec.com
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.